Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Weight and raises the price target from $515 to $566.
Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Weight and raises the price target from $515 to $566.